Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP002004) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
Bicyclic peptide BT5528
|
|||||
| Synonyms |
BT-5528
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase II | |||||
| Sequence Length | 29 | |||||
| SBP Sequence |
>Bicyclic peptide BT-5528
[B-Ala][Sar][Sar][Sar][Sar][Sar][Sar][Sar][Sar][Sar][Sar]A[H Arg]DC[HyP]LVNPLCLHP[d-Asp]W[HArg]C |
|||||
| Sequence Description | TATA is linked via three cysteine residues. | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS017 | [1] , [2] | ||||
| Scaffold Name | Bicyclic peptide | |||||
| Scaffold Class | Non-Antibody | |||||
| Fold Type | Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| Ephrin type-A receptor 2 | Inhibitor | Non-small cell lung cancer [ICD-11: 2C25.Y]; Breast cancer [ICD-11: 2C6Z]; Bladder cancer [ICD-11: 2C94.Z]; Esophageal cancer [ICD-11: 2B70.Z]; Gastric cancer [ICD-11: 2B72.Z]; Ovarian cancer [ICD-11: 2C73.Z] | N.A. | Bicycle Therapeutics | [1] , [2] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT04180371 | Click to show the Detail | |||||
| Indication | Advanced Malignancies | |||||
| Phase | Phase I; Phase II | |||||
| Title | Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of?BT5528?in Patients With Advanced Malignancies Associated With EphA2 Expression | |||||
| Status | Recruiting | |||||
| Sponsor | Bicycle Tx Limited | |||||